peptides
Tirzepatide 20mg
A 20mg Tirzepatide vial pairing GLP-1 with GIP receptor activity — researched for superior weight reduction and metabolic improvement vs single-agonist analogs.
Research-observed benefits
- ›Strong appetite reduction
- ›Superior fat loss
- ›Lipid improvements
- ›Metabolic flexibility
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
Reconstitution helper
Suggested: 3 mL BAC water → 6.67 mg/mL
CAS Number
—
Purity
99%+
Molecular Formula
—
Stock
120 units
Order type
Purchase option
Quantity
Total
$60
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
Tirzepatide 20mg — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Dual GLP-1 / GIP receptor agonist. Combines incretin pathways for stronger insulinotropic and appetite-suppressing effects than single agonists.
How It Helps
Among the most effective peptides in published weight-loss and glycemic-control research — superior to Semaglutide in head-to-head trials.
Half-Life
~5 days; once-weekly dosing.
Onset of Effects
Appetite suppression within days; weight effects compounding through 24+ weeks.
Administration
Subcutaneous, abdomen/thigh/upper arm.
Storage
Lyophilized frozen; reconstituted refrigerated, 28 days.
Reconstitution Guide
10 mg + 2 mL BAC → 5 mg/mL.
Precise Dosing Protocols
SURMOUNT titration
- Dose:
- 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly
- Frequency:
- Once weekly SC
- Duration:
- 20-week titration + maintenance
- Notes:
- Step up every 4 weeks if tolerated
Stacks Well With
- ›MOTS-c
- ›Tesamorelin (lean retention)
- ›NAD+ (energy in deficit)
Research-Observed Side Effects
- •Nausea (titration)
- •Constipation/diarrhea
- •Reduced appetite for water — monitor hydration
- •Mild fatigue early
Translational Cautions
- •MTC/MEN2 history
- •Active pancreatitis
Cycling Guidance
Long study arcs; taper at the end of research window.
Research Highlights
- ▸SURMOUNT-1: up to 22.5% weight reduction at 72 weeks, 15 mg dose.
- ▸Superior glycemic control vs Semaglutide in SURPASS-2.